Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

A systematic study of 50S ribosomal subunit purification enabling robust crystallization.

McLellan TJ, Marr ES, Wondrack LM, Subashi TA, Aeed PA, Han S, Xu Z, Wang IK, Maguire BA.

Acta Crystallogr D Biol Crystallogr. 2009 Dec;65(Pt 12):1270-82. doi: 10.1107/S0907444909039043. Epub 2009 Nov 17.

PMID:
19966413
2.

Purification of the large ribosomal subunit via its association with the small subunit.

Simons SP, McLellan TJ, Aeed PA, Zaniewski RP, Desbonnet CR, Wondrack LM, Marr ES, Subashi TA, Dougherty TJ, Xu Z, Wang IK, LeMotte PK, Maguire BA.

Anal Biochem. 2009 Dec 1;395(1):77-85. doi: 10.1016/j.ab.2009.07.042. Epub 2009 Jul 30.

PMID:
19646947
3.

A novel chromatography system to isolate active ribosomes from pathogenic bacteria.

Maguire BA, Wondrack LM, Contillo LG, Xu Z.

RNA. 2008 Jan;14(1):188-95. Epub 2007 Nov 12.

4.

Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.

Tait-Kamradt A, Davies T, Appelbaum PC, Depardieu F, Courvalin P, Petitpas J, Wondrack L, Walker A, Jacobs MR, Sutcliffe J.

Antimicrob Agents Chemother. 2000 Dec;44(12):3395-401.

5.

CJ-12,373, a novel topoisomerase II inhibitor: fermentation, isolation, structure elucidation and biological activities.

Inagaki T, Kaneda K, Suzuki Y, Hirai H, Nomura E, Sakakibara T, Yamauchi Y, Huang LH, Norcia M, Wondrack LM, Sutcliffe JA, Kojima N.

J Antibiot (Tokyo). 1998 Feb;51(2):112-6.

6.

mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae.

Tait-Kamradt A, Clancy J, Cronan M, Dib-Hajj F, Wondrack L, Yuan W, Sutcliffe J.

Antimicrob Agents Chemother. 1997 Oct;41(10):2251-5.

7.

Detection of erythromycin-resistant determinants by PCR.

Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L.

Antimicrob Agents Chemother. 1996 Nov;40(11):2562-6.

8.

Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection.

Bergeron J, Ammirati M, Danley D, James L, Norcia M, Retsema J, Strick CA, Su WG, Sutcliffe J, Wondrack L.

Antimicrob Agents Chemother. 1996 Sep;40(9):2226-8.

10.

Clinical strain of Staphylococcus aureus inactivates and causes efflux of macrolides.

Wondrack L, Massa M, Yang BV, Sutcliffe J.

Antimicrob Agents Chemother. 1996 Apr;40(4):992-8.

11.

CJ-12,371 and CJ-12,372, two novel DNA gyrase inhibitors. Fermentation,isolation, structural elucidation and biological activities.

Sakemi S, Inagaki T, Kaneda K, Hirai H, Iwata E, Sakakibara T, Yamauchi Y, Norcia M, Wondrack LM, Sutcliffe JA, et al.

J Antibiot (Tokyo). 1995 Feb;48(2):134-42.

12.
13.

Characterization of growth hormone releasing factor analog expression in Saccharomyces cerevisiae.

Craig WS, Wondrack L, Siegel R, Patthi S, Davis GR, Velicelebi G, Mowles TF, Thill GP.

Int J Pept Protein Res. 1991 Nov;38(5):401-8.

PMID:
1802859
14.

Insoluble glucan synthesis by Streptococcus mutans serotype c strains.

Kuramitsu HK, Wondrack L.

Infect Immun. 1983 Nov;42(2):763-70.

15.

Genetic transformation of putative cariogenic properties in Streptococcus mutans.

Perry D, Wondrack LM, Kuramitsu HK.

Infect Immun. 1983 Aug;41(2):722-7.

16.

Interaction of Streptococcus mutans glucosyltransferases with teichoic acids.

Kuramitsu HK, Wondrack L, McGuinness M.

Infect Immun. 1980 Aug;29(2):376-82.

18.

Urea: obligate intermediate of pyrimidine-ring catabolism in Rhodosporidium toruloides.

Thwaites WM, Davis CH, Wallis-Biggart N, Wondrack LM, Abbott MT.

J Bacteriol. 1979 Mar;137(3):1145-50.

19.
20.

Supplemental Content

Loading ...
Support Center